New Delhi: Today the government said that approval for human clinical trials for two made-in-India COVID-19 vaccine – COVAXIN and ZyCov-D – marks the “beginning of the end” for the novel coronavirus pandemic. It has infected over 1.12 crore people worldwide and left more than 5.3 lakh people dead all over the world.
The ministry said that in India, “six Indian companies are working on a COVID-19 vaccine. Along with two Indian vaccines, COVAXIN and ZyCov-D, the world over 11 out of 140 vaccine candidates are in human trials”.
He also said that the manufacturers of two of the leading candidates – AZD1222 (British firm AstraZeneca) and mRNA-1273 (US-based Moderna) – had signed production agreements with Indian companies should their vaccines prove safe and also effective.
COVAXIN and ZyCov-D both have been approved for both Phase II, and also III trials. Each phase can take months, or even years, to in fully completed. The first two phases of drug trials test for safety while the third tests the effectiveness of the medicine
On August 15, the occasion of Independence Day, the ministry’s statement comes amid a row over a letter by the ICMR (Indian Council for Medical Research) setting as the target for releasing a coronavirus vaccine on that day.
This week, India’s COVID-19 Vaccine “Covaxin” developed by Hyderabad-based Bharat Biotech. And also “ZyCov-D-” developed by Zydus Cadila, approved for Phase I, II trials. COVAXIN’s phase I trials completed in 28 days. Now, phase II and also III have not completed.
All over the world, dozens of vaccine candidates are at different stages of development to unravel the Coronavirus epidemic.
In India, more than 6.7 lakh confirmed COVID-19 cases. So, the manufacturer of the “COVAXIN and ZyCov-D” vaccine awaited for these medicines works better.
Visit more about it on guzubit.com